| Assessment Status |
Rapid Review Complete |
| HTA ID |
25012 |
| Drug |
Ravulizumab |
| Brand |
Ultomiris® |
| Indication |
Ravulizumab (Ultomiris®) is indicated as an add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis who are anti-acetylcholine receptor antibody-positive. |
| Rapid review commissioned |
17/02/2025 |
| Rapid review completed |
12/03/2025 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ravulizumab compared with the current standard of care. |
